The development of new immunotherapies for the treatment of cancer using interleukin-2. A review (Q39512710)

12 September 2017

1 reference

title

The development of new immunotherapies for the treatment of cancer using interleukin-2. A review (English)

1 reference

12 September 2017

1 reference

Rosenberg SA

1

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 August 1988

1 reference

12 September 2017

1 reference

12 September 2017

volume

208

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

121-135

1 reference

Generation of cytotoxic T lymphocytes to autologous human leukaemia cells by sensitisation to pooled allogeneic normal cells

12 September 2017

cites work

1 reference

12 December 2020

In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

1 reference

12 December 2020

The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors

1 reference

12 December 2020

Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens

1 reference

12 December 2020

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor

1 reference

12 December 2020

Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

12 December 2020

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

12 December 2020

Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization

1 reference

12 December 2020

Lysis of fresh natural killer-resistant tumor cells by lectin-activated syngeneic and allogeneic murine splenocytes.

1 reference

12 December 2020

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

1 reference

12 December 2020

Adoptive immunotherapy of cancer: accomplishments and prospects

1 reference

12 December 2020

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

12 December 2020

The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

1 reference

12 December 2020

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

1 reference

12 December 2020

Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2

1 reference

12 December 2020

Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer

1 reference

12 December 2020

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

12 December 2020

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo

1 reference

12 December 2020

Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues

1 reference

12 December 2020

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma

1 reference

12 December 2020

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.

1 reference

12 December 2020

Functional characterization of T lymphocytes propagated from human lung carcinomas

1 reference

12 December 2020

Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.

1 reference

12 December 2020

In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells

1 reference

12 December 2020

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells

1 reference

12 December 2020

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice

1 reference

12 December 2020

Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice

1 reference

12 December 2020

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

12 December 2020

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

1 reference

12 December 2020

Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models

1 reference

12 December 2020

Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2

1 reference

12 December 2020

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases

1 reference

12 December 2020

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer

1 reference

12 December 2020

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

1 reference

12 December 2020

Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2

1 reference

12 December 2020

Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy

1 reference

12 December 2020

Separation and functional studies of the human lymphokine-activated killer cell.

1 reference

12 December 2020

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials

1 reference

12 December 2020

Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors

1 reference

12 December 2020

Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity

1 reference

12 December 2020

10.1097/00000658-198808000-00001

Identifiers

DOI

1 reference

12 September 2017

1 reference